ENDPOINTS

Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger

Acelyrin rejects buyout offer from Tang’s Concentra, st...

Mar 4, 2025 0

The board of immunology biotech Acelyrin has rejected the buyout offer from Tang...

Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval

Tenaya raises about $53M; BeiGene’s PD-1 gets a first-l...

Mar 4, 2025 0

Plus, news about Evotec and Osivax: Tenaya Therapeutics’ $52.5M public offer...

Bourla says Pfizer could transfer production to US to sidestep Trump's tariffs

Bourla says Pfizer could transfer production to US to s...

Mar 4, 2025 0

Pfizer could “quickly” transfer operations from foreign sites to its US manufact...

UnitedHealthcare’s copay-only plan is booming, despite backlash over care denials

UnitedHealthcare’s copay-only plan is booming, despite ...

Mar 4, 2025 0

Business is booming for UnitedHealthcare’s transparent-pricing health plan, as m...

NIH-backed research tries to use stem cells to restore the eye’s outer layer

NIH-backed research tries to use stem cells to restore ...

Mar 4, 2025 0

13 out of 14 people with eye damage experienced at least some improvements to th...

23andMe rejects CEO's second take-private offer

23andMe rejects CEO's second take-private offer

Mar 4, 2025 0

A special committee of 23andMe's board rejected CEO Anne Wojcicki's latest offer...

Sofinnova Partners raises €1.2B to invest in life sciences

Sofinnova Partners raises €1.2B to invest in life sciences

Mar 4, 2025 0

Sofinnova Partners has raised €1.2 billion ($1.26 billion) across its various in...

Cerebral CEO David Mou has stepped down

Cerebral CEO David Mou has stepped down

Mar 3, 2025 0

The CEO of mental health startup Cerebral stepped down in December 2024, Endpoin...

GSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition

GSK, Amgen and AstraZeneca tout Phase 3 data in inflamm...

Mar 3, 2025 0

GSK, Amgen and AstraZeneca released positive data supporting their rival drugs i...

Genentech's TNKase gets new approval; Sanofi gives up rights to oncology candidate

Genentech's TNKase gets new approval; Sanofi gives up r...

Mar 3, 2025 0

Plus, news about Nuvation Bio and Leqembi: Sanofi gives back rights to Biond...

Pliant calls it quits on Phase 2b IPF study

Pliant calls it quits on Phase 2b IPF study

Mar 3, 2025 0

Pliant Therapeutics has officially discontinued a mid-stage study of its chronic...

Biohaven’s ion channel drug fails pivotal bipolar mania study

Biohaven’s ion channel drug fails pivotal bipolar mania...

Mar 3, 2025 0

Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania...

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

Protagonist, Takeda's profit sharing deal under spotlig...

Mar 3, 2025 0

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide —...

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Novartis licenses Kyorin’s preclinical chronic hives ca...

Mar 3, 2025 0

Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s pre...

Nuvation Bio’s $250M funding; Leqembi rejected again in Australia

Nuvation Bio’s $250M funding; Leqembi rejected again in...

Mar 3, 2025 0

Plus, news about IN8bio and Syros: Nuvation Bio’s new funding: The New York ...

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

Novo Nordisk signs $354M partnership with AI-guided bio...

Mar 3, 2025 0

Novo Nordisk has formed a $354 million research collaboration with Gensaic, the ...

29
30
31
32
33

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.